Fig. 3From: Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil countsKaplan–Meier product limit estimates of percentages of patients with eosinophil counts greater than zero over time on mepolizumab and menralizumab therapiesBack to article page